期刊
NATURE REVIEWS DRUG DISCOVERY
卷 14, 期 8, 页码 543-560出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd4626
关键词
-
资金
- US National Institutes of Health (NIH) [T32 GM007175]
- NIH [GM61390]
- NIH Pharmacogenomics Research Network [GM61390]
- Burroughs Wellcome Fund Innovation in Regulatory Sciences grant [1012485, DK103729]
- Canadian Institutes of Health Research [MOP-89753, DSEN-PREVENT FRN-117588]
- Ontario Institutes for Cancer Research
- Cancer Care Ontario
- Program of Experimental Medicine in the Department of Medicine at Western University, in Ontario, Canada
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK103729, P30DK026743] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM061390, U19GM061390, T32GM007175] Funding Source: NIH RePORTER
Solute carrier (SLC) transporters a family of more than 300 membrane-bound proteins that facilitate the transport of a wide array of substrates across biological membranes have important roles in physiological processes ranging from the cellular uptake of nutrients to the absorption of drugs and other xenobiotics. Several classes of marketed drugs target well-known SLC transporters, such as neurotransmitter transporters, and human genetic studies have provided powerful insight into the roles of more-recently characterized SLC transporters in both rare and common diseases, indicating a wealth of new therapeutic opportunities. This Review summarizes knowledge on the roles of SLC transporters in human disease, describes strategies to target such transporters, and highlights current and investigational drugs that modulate SLC transporters, as well as promising drug targets.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据